文献速递认知障碍与谵妄多重用药老年慢病共病管理

阿尔茨海默病诊断前后症状性与预防性药物使用变化:10年匹配队列研究

Symptomatic and Preventive Medication Use before and after Alzheimer's Disease Diagnosis: A 10-Year Matched Cohort Study.
PubMed 文献 · J Am Med Dir Assoc · 2024-05-01

该回顾性匹配队列研究纳入芬兰58,496名经老年科或神经科医生确诊的阿尔茨海默病(AD)患者,按年龄、性别和地区1:1匹配无AD对照,分析诊断前5年至诊断后5年每6个月的症状性与预防性药物使用情况。结果显示AD患者诊断前1年症状性与预防性药物增加幅度均高于对照,诊断后5年预防性药物使用下降而对照上升,抗精神病药和抗抑郁药使用绝对增幅显著高于对照。

要点

  • AD患者诊断前1年≥3种症状性药物和≥3种预防性药物的使用增幅均高于无AD对照。
  • 诊断后5年AD患者≥3种预防性药物使用下降6.0%,而无AD对照上升6.1%。
  • 随访期间AD患者抗精神病药和抗抑郁药使用绝对增幅分别为22.7%和1.8%、19.1%和5.0%,均高于对照。

核心结论

  • AD诊断时点及诊断后,人群层面药物使用发生显著变化,表现为预防性药物停用而症状性药物变化较小。

研究设计与样本

  • 回顾性匹配队列研究,纳入芬兰58,496名经老年科或神经科医生确诊的AD患者,按年龄、性别和地区1:1匹配无AD对照。
  • 药物发放数据来自芬兰处方登记,从诊断前5年至诊断后每6个月评估症状性与预防性药物使用 prevalence。
  • 采用有序逻辑回归比较AD组与无AD组的纵向药物使用变化。

主要发现

  • 诊断前5年至诊断后5年,AD组与无AD组在症状性药物(P < .001)和预防性药物(P = .006)使用上存在差异。
  • 诊断前5年,两组症状性和预防性药物使用 prevalence 均增加。
  • 诊断前1年,AD组使用≥3种症状性药物的增幅为+4.4%,无AD组为+2.2%;使用≥3种预防性药物的增幅为+6.4%,无AD组为+2.9%。
  • 诊断后5年,两组症状性药物使用趋于平稳;AD组使用≥3种预防性药物下降6.0%,无AD组上升6.1%。
  • 随访期间,AD组抗精神病药使用绝对增幅为+22.7%(无AD组+1.8%),抗抑郁药为+19.1%(无AD组+5.0%);AD组对乙酰氨基酚和钙补充剂使用分别增加31.1%和20.4%。

临床怎么用

  • AD诊断前后应加强药物评估,关注预防性药物(如他汀、β受体阻滞剂)的继续使用是否仍有获益。
  • 需警惕诊断前后抗精神病药和抗抑郁药使用显著增加,评估其适应证与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate longitudinal changes in symptomatic and preventive medication use among community-dwelling people with and without Alzheimer's disease (AD) 5 years pre- and post-AD diagnosis. DESIGN: Retrospective matched cohort study. SETTINGS AND PARTICIPANTS: The sample comprised 58,496 people with a geriatrician/neurologist-verified AD diagnosis matched 1:1 for age, sex, and region to people without AD in Finland. METHODS: Medication dispensing data were obtained from the Finnish Prescription Register. Prevalence of symptomatic and preventive medication use was evaluated every 6 months from 5 years pre- to post-AD diagnosis. Longitudinal changes in medication use between people with and without AD were compared using ordinal logistic regression. RESULTS: During the 5 years pre- and post-diagnosis, there were differences in symptomatic (P < .001) and preventive (P = .006) medication use between people with and without AD. Over the 5 years pre-diagnosis, prevalence of symptomatic and preventive medications increased in both people with and without AD. During the 1 year pre-diagnosis, people with AD had a higher increase in use of ≥3 symptomatic medications (+4.4% vs +2.2%) and ≥3 preventive medications (+6.4% vs +2.9%) compared to people without AD. Over the 5 years post-diagnosis, symptomatic medication use plateaued in both people with and without AD. Meanwhile, people using ≥3 preventive medications decreased (-6.0%) in those with AD, but increased (+6.1%) in those without AD. During the follow-up period, people with AD had a larger absolute percentage increase in prevalence of antipsychotics (+22.7% vs +1.8%) and antidepressants (+19.1% vs +5.0%) than people without AD. During the same period, paracetamol and calcium supplement use increased by 31.1% and 20.4%, respectively, among people with AD. The largest absolute percentage decrease in prevalence of preventive medications over the 5 years post-diagnosis were beta-blockers (-9.8%) and statins (-7.0%) in people with AD. CONCLUSIONS AND IMPLICATIONS: At the point of and following diagnosis, there were population-level changes in medication use among people with AD. Medication assessments during this period appear to coincide with discontinuation of preventive medications whereas minimal changes were observed in symptomatic medication use.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Liau SJ, Bell JS, Lalic S, et al. Symptomatic and Preventive Medication Use before and after Alzheimer's Disease Diagnosis: A 10-Year Matched Cohort Study. J Am Med Dir Assoc. 2024. PMID: 38702043. doi:10.1016/j.jamda.2024.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。